Glycogen synthase kinase 3 (GSK3) inhibits signaling pathways that are essential for bone development. To study the requirement for GSK activity during endochondral bone development, we inhibited GSK3 in cultured metatarsal bones with pharmacological antagonists. Interestingly, we find that inhibition of GSK3 strongly repressed chondrocyte and perichondrial osteoblast differentiation. Moreover, chondrocyte proliferation was inhibited, whereas perichondrial cell proliferation was stimulated. These results mirror the effects of fibroblast growth factor signaling (FGF), suggesting the FGF expression is induced. Indeed, we showed that (1) FGF18 expression is stimulated following inhibition of GSK3 and (2) GSK3 regulates FGF18 expression through the control of h-catenin levels. Stimulation of cultured metatarsal with FGF18 had similar effects on the differentiation and proliferation of chondrocytes and perichondrial cells as GSK3 repression. This suggests that the regulation of FGF18 expression is a major function of GSK3 during endochondral bone development. Consistent with this, we showed that the effect of GSK3 inhibition on chondrocyte proliferation is repressed in tissues lacking a receptor for FGF18, FGF receptor 3. D
Introduction
Endochondral bone formation is an exquisitely controlled process requiring both chondrocyte and osteoblast differentiation. During this process, chondrocytes sequentially differentiate through a series of stages to eventually become hypertrophic chondrocytes. Cells in the surrounding perichondrium differentiate in step with the chondrocytes and eventually form osteoblasts, which secrete a collar of bone around the chondrocytes (Ballock and O'Keefe, 2003; Kronenberg, 2003; van der Eerden et al., 2003) . The molecular events that control endochondral bone development are incompletely understood. However, genetic and biochemical studies have defined certain signaling and transcriptional pathways as essential for endochondral development. For example, Indian hedgehog is vital for chondrocyte and osteoblast differentiation (Lanske et al., 1996; St-Jacques et al., 1999; Vortkamp et al., 1996) . Also, the transcription factor nuclear factor of activated T-cells (NFAT) performs important functions during cartilage gene expression and the differentiation of chondrocyte precursors (Tomita et al., 2002) . Additionally, canonical Wnt signaling through h-catenin is required for normal chondrocyte and osteoblast differentiation Guo et al., 2004; Hu et al., 2005) . Significantly, each of these disparate pathways is regulated by a common kinase, glycogen synthase kinase 3 (GSK3).
GSK3 is a ubiquitously expressed kinase that regulates diverse cellular processes ranging from metabolism to cell fate specification (Cohen and Frame, 2001 ). Though first described as the kinase that regulates glycogen synthesis (Hemmings et al., 1981) , GSK3 is now recognized to regulate developmental pathways including Wnt and hedgehog signaling pathways. Hedgehog signals through the smoothed/patched receptor complex and stimulates the activity of the transcription factor cubitus interruptus (Gli is the vertebrate ortholog). GSK3 inhibits hedgehog signaling by phosphorylating cubitus interruptus, thereby inducing conversion to a transcriptional repressor (Jia et al., 2002; Price and Kalderon, 2002) . GSK3 also inhibits the transcription factor NFAT. Phosphorylation of the aminoterminal regulatory domain by GSK3 results in nuclear export of NFAT (Okamura et al., 2000) , thereby inhibiting transcriptional activity. Wnt signaling is antagonized by GSK3 through phosphorylation of h-catenin. h-catenin phosphorylation results in ubiquitin-dependent degradation through the proteosome. Because each of these signaling cascades is essential for bone and cartilage differentiation, we hypothesize that GSK3 activity must be tightly regulated during endochondral bone development.
Unlike many kinases, GSK3 is constitutively active. Additionally, while many kinases are activated following stimulus-dependent phosphorylation, GSK3 is inactivated following phosphorylation. Several kinases including PKA, p70S6 kinase, AKT and others catalyze phosphorylation of a serine residue near the amino-terminus of GSK3 (Cross et al., 1995; Fang et al., 2000; Stambolic and Woodgett, 1994) . This phosphoserine then binds to the active site and strongly inhibits GSK3 . Wnt signaling through disheveled also inhibits GSK3, although the mechanism of inhibition is not entirely clear. Therefore, a large number of signaling pathways and extracellular ligands all inhibit the activity of GSK3. Because GSK3 is a constitutive kinase that is exclusively regulated through repressor pathways, we reasoned that we could best understand the function of GSK3 in endochondral development by repressing GSK3 activity. To investigate the requirement for GSK activity during endochondral bone development, we used the pharmacological antagonists of GSK3, lithium and SB216763 (Coghlan et al., 2000; Stambolic et al., 1996) . We find that GSK3 activity is essential for endochondral bone development. Inhibition of GSK3 with SB216763 repressed chondrocyte and osteoblast differentiation in cultured metatarsals from mouse embryo. Significantly, GSK3 repression induces fibroblast growth factor 18 (FGF18) expression and in turn, FGF18 repressed chondrocyte and osteoblast differentiation. These results suggest a pathway whereby GSK regulates endochondral bone development through the control of FGF18 expression. In support of this, we showed that effects on GSK3 on chondrocyte proliferation are absent in metatarsal lacking the FGF18 receptor, fibroblast growth factor receptor 3.
Materials and methods

Reagents
Reagents were purchased from suppliers as follows: SB216763 from Tocris (Cookson, MO); lithium chloride from Sigma (St. Louis, MO); FGF18 Peprotech (Rocky Hill, NJ) .
Metatarsal cultures
Metatarsals were dissected from 15.5 day C57Bl/6 or FGF receptor 3 null embryos and cultured in serum free alpha MEM (Invitrogen) containing with 0.005 mg/ml ascorbic acid, 0.3 mg/ml l-glutamine, 0.05 mg/ml gentamicin, 1 mM h-glycerophosphate and 0.2% bovine serum albumin. The genotyping of FGF receptor 3 mice was done as previously described (Colvin et al., 1996) . Tissue explants were grown at 37-C in a humidified 5% CO 2 incubator. To ensure that comparison was made between samples with equivalent states of differentiation, the tissues were maintained as right and left pairs from a given embryo and cultured in neighboring wells of a 24 well cluster plate. All comparisons were made using matched pairs. For histological analyses, the samples were paraffin embedded following fixation in 4% buffered paraformaldehyde for 1 h at room temperature. 4; Wang et al., 1999) was obtained from the ATCC (Manassas, VA), cultured in a-MEM containing 10% fetal bovine serum (Hyclone), 2 mM l-glutamine, penicillin G (100 units/ml) and streptomycin (100 Ag/ml) at 37-C in a humidified 5% CO 2 incubator. All cells were transfected in triplicate using a modified calcium phosphate precipitate and assayed for luciferase or h-galactosidase activity as previously described Reinhold et al., 2004b) . The FGF18 luciferase plasmid contained a 3.4 kb MscI fragment of the mouse FGF18 gene (extending from approximately À3.3 kb relative to the transcriptional start site) cloned into pGL3basic (Promega).
Cell culture and transfection
MC3T3E1 (clone
Immunofluorescence
4 Am paraffin sections were warmed to 70-C for 10 min, then deparafinized and re-hydrated with a graded alcohol series. Antigen retrieval was done for 20 min in 10 mM pH 6.0 citrate buffer heated to 95-C prior to immersion of the slides. Thereafter, the slides were washed with phosphate buffered saline (PBS) and blocked in 1% fraction-V heat shock treated bovine serum albumin (Fisher), 5% normal goat or rabbit serum (Jackson ImmunoResearch Laboratories), 0.1% Triton X-100, in PBS. After 1 h, the blocking buffer was removed and replaced with 50 Al of blocking buffer containing the primary antibody (h-catenin Santa Cruz, sc7963 or N-cadherin, Transduction Labs, 610920) at a 1:200 dilution. Slides remained in the humidified chamber and incubated at 4-C overnight. The slides were washed three times with PBS containing 0.1% TX-100 and then blocked for 1 h at room temperature. Secondary antibody was applied (CY3-goat anti-mouse, Jackson ImmunoResearch Laboratories) for 1 h at room temperature at a 1:800 dilution. The samples were washed three times in PBS and mounted with Pro-Long Anti-fade reagent (Molecular Probes). Images were obtained with a Zeiss Axioscope 2 fitted with 40Â (NA 1.3) and 63Â (NA 1.4) objectives. Deconvolution was done using Zeiss Axiovision software.
BrdU labeling
Tissues were pulse-labeled with 10 AM 5-bromo-2-deoxyuridine (Sigma) for 3 h. Tissues were then washed with PBS, paraffin embedded and sectioned to 4 Am. Slides were deparafinized, hydrated and immersed for 30 min in PBS containing 10% methanol and 3% hydrogen peroxide. After washing with PBS, the tissues were digested with 400 Ag/ml pepsin (Sigma) containing 0.01 N HCl for 30 min at room temperature, neutralized for 10 min in 0.1 M borate pH 8.5, then rinsed with PBS. BrdU was detected with the Vectastain ABC kit (Vector Labs PK-4002) according to the manufacturer's protocol using an anti-BrdU antibody (Sigma B-2531). The labeling index was calculated by counting the number of BrdUlabeled nuclei and divided by the total number of cells within a grid drawn using Photoshop (Adobe). Equal areas of chondrocytes were counted in the control and treatment groups. For perichondrial cells, the entire perichondrium was counted. P values were determined using a paired Student's t test. The null hypothesis was rejected for P < 0.05.
Real time quantitative PCR
Total RNA was extracted by homogenizing metatarsals using RNA-Bee (Tel-Test, Inc.) according to the manufacturer's protocol. One microgram of RNA was reverse transcribed in 25 Al at 42-C for 2 h using TaqMan reverse transcription reagents with random hexamers according to manufacturer directions (Applied Biosystems). Quantitative PCR was performed in the ABI Prism 7000 Sequence Detection System according to manufacturer's directions (Applied Biosystems). 25 Al PCR reactions were made of SYBR Green 2Â PCR Master Mix (Applied Biosystems), 5 pmol of each forward and reverse primer and 3 Al of cDNA. Cycling conditions were 50-C for 2 min, 95-C for 10 min followed by 40 cycles of 15 s at 95-C and 60 s at 60-C. Primers were designed using PrimerExpress (Applied Biosystems). Oligonucleotides used were as follows: FGF1-5V-CGGCTCGCAGACACCAA-3V, 5V-ACCAGTTCTTCTCC-GCATGCT-3V; FGF2-5V-GGACCCCAAGCGGCTCTA-3V,  5V-CCTCTCTCTTCTGCTTGGAGTTGT-3V; FGF3-5V-GTGAACGGCAGCCTTGAGA-3V, 5V-CAGGTACCGC-CCAGAAAAGA-3V; FGF4-5V-CGAGGCGTGGTGAGC-ATCT-3V, 5V-CGTTGTAGTTGTTGGGCAGAAGT-3V;  FGF7-5V-TGAAGAACAGCTACAACATCATGGA-3V, 5V-TCAGTTCTTTGAAGTTGCAATCCT-3V; FGF8-5V-CTC-ATTGTGGAGACCGATACTTTTG-3V, 5V-GCCGTTGCT-CTTGGCAATT-3V; FGF9-5V-ATCTTCCCCAACGGTAQ  CTATCCA-3V; 5V-CTCGTTCATGCCGAGGTAGAGT-3V;  FGF10-5V-AGTGCGGGAAGGCATGTG-3V, 5V-CTCCGA-TTTCCACTGATGTTATCTC-3V; FGF11-5V-TCCTTCAC-CCACTTCAATCTGA-3V, 5V-TGAAATGTGGCGAGCTGQ  TACA-3V; FGF12-5V-AACCCCAGCTGAAAGGGATT-3V,  5V-GCCACCACACGCAGTCCTA-3V; FGF13-5V-AGGAGA-CCAGAGCCTCAGCTT-3V, 5V-CGTCTTTGGTGCCATC-AATG-3V; FGF14-5V-GCTCTCGATGGAACCAAGGA-3V,  5V-TTGCTATGTACAACCCTGTCTTCAC-3V; FGF18-5V-ACTGCTGTGCTTCCAGGTTC-3V, 5V-CCCAGGACTTG-AATGTGCTT-3V ; FGF20-5V-GGATCACAGTCTCTTCGG- TATCCT-3V, 5V-TTTGTCATTCATCCCAAGGTACAG-3V;  FGF22-5V-CTTCTCCTCCACTCACTTTTTCCT-3V; 5V-GCC-TGAGTACACAGCTTTGATCAC-3V; aggrecan-5V-ACTG-CAGCGATGACCCTC-3V, 5V-GGAATCCCTAGCTGCTTCQ  G-3V; collagen II-5V-GAAGGTGGAAAGCAAGGTGA-3V,  5V-CATCAGTACCAGGAGTGCCA-3V; conduction-5V-AA-AACGGATTCAGGTCCTTCAA-3V; 5V-GTCAGTGCGTC-GCTGGATAAC-3V ; Indian hedgehog-5V-CAATCCCGAQ CATCATCTTCA-3V; 5V-GCGGCCCTCATAGTGTAAAG-3V.
In situ hybridization
4 Am sections of paraffin embedded tissues were processed, hybridized and washed according to the mRNA locator protocol (Ambion). The FGF18 (gift from D. Ornitz, St. Louis, MO) and collagen type X (B. Olson Boston, MA) riboprobes were labeled as previously described .
Results
To understand how GSK3 controls endochondral bone formation, we studied the differentiation of mouse embryo metatarsals in organ culture. This is an established method for investigating the differentiation of chondrocytes and osteoblasts during endochondral bone development (Dieudonne et al., 1994; Serra et al., 1999) . Mouse metatarsal bone rudiments were prepared from 15.5 day embryos and cultured in serum-free medium. At the time of isolation, the bone rudiments contain immature chondrocytes surrounded by a sheath of undifferentiated perichondrial cells (Fig. 1A) . Osteoblasts and hypertrophic chondrocytes are absent. After 3 -4 days in serum-free medium, chondrocyte hypertrophy begins (Fig. 1A) . Simultaneously, cells in the perichondrium differentiate into osteoblasts and secrete a collar of woven bone around the hypertrophic chondrocytes. The mature osteoblasts synthesizing the collar of bone are identified by the presence of N-cadherin organized into adherens junctions (Fig. 1A) .
To investigate how GSK3 regulates endochondral bone formation in metatarsals, we used specific pharmacological antagonists of GSK3. GSK3 is a constitutive kinase that is regulated through repressor pathways. Therefore, we modeled the regulation of GSK3 using the pharmacological inhibitors lithium and SB216763. Interestingly, endochondral bone development was strikingly inhibited following inhibition of GSK3 with either lithium or SB216763 for 48 h. This was evidenced by substantial or complete inhibition of chondrocyte hypertrophy in the samples treated with the GSK3 inhibitors lithium and SB216763 (Figs. 1B -D) . And is further evidenced by the repression of type X collagen expression, a marker for hypertrophic chondrocytes (Fig.  1E) . In addition to the inhibition of chondrocyte differentiation, we observed a concomitant inhibition of perichondrial osteoblast differentiation. This was evidenced by the absence of a collar of woven bone surrounding the hypertrophic chondrocytes (compare the right panels of Figs. 1B and D), the absence of osteoblasts containing Ncadherin organized into adherens junctions (Fig. 1F ) and dramatically reduced expression of type I collagen (Fig.  1G) . Note that scattered chondrocytes contain detectable levels of N-cadherin following treatment with SB216763. Immature chondroblasts express N-cadherin (Oberlender and Tuan, 1994a,b) . The presence of N-cadherin in these cells reflects the strong repression of differentiation and immature phenotype of these cells.
To further characterize the effects of GSK3 on chondrocyte differentiation, we performed quantitative RT-PCR with RNA extracted from metatarsals. Corroborating the in situ hybridization data of Fig. 1E , inhibition of GSK3 repressed the expression of type X collagen greater than 3000-fold as measured by quantitative real time PCR (data not shown). Also, other chondrocyte-specific genes were inhibited. The expression of both type II collagen and aggrecan was dramatically repressed following inhibition of GSK3 (Fig. 2) . Also, the expression of Indian hedgehog and patched, the hedgehog receptor, was repressed in these samples. Because patched is both a receptor and transcriptional target of Indian hedgehog, these findings suggest that hedgehog signaling was repressed. Notice that the expression of conductin, a transcriptional target of h-catenin , was induced following inhibition of GSK3.
To investigate if GSK3 also regulated cell proliferation, we performed bromodeoxyuridine (BrdU) labeling experiments. Metatarsal samples were treated with the GSK3 inhibitor SB216763 and thereafter pulsed with BrdU for 3 h. Proliferating cells were identified by immunostaining for BrdU. Interestingly, inhibition of GSK3 had opposite effects on chondrocyte and perichondrial cell proliferation (Fig. 3) . Inhibition of GSK3 repressed chondrocyte proliferation (Fig. 3B ), whereas perichondrial cell proliferation was stimulated following inhibition of GSK3 (Fig. 3C) . Significantly, these data showing inhibition of chondrocyte differentiation and proliferation resemble the effects of FGF signaling in cartilage (Deng et al., 1996; Kato and Iwamoto, 1990; Li et al., 1999; Naski et al., 1998) and are similar to results obtained when bone explants are stimulated with FGF (Mancilla et al., 1998) .
Because these results suggest augmented FGF signaling, we hypothesized that inhibition of GSK3 stimulates FGF expression. To test this, we determined FGF expression by quantitative real time PCR. Interestingly, we observed that FGF13 and FGF18 were substantially induced following the inhibition of GSK3 (Fig. 4A ). The induction of FGF18 is intriguing because FGF18 is an essential regulator of endochondral bone development Ohbayashi et al., 2002) . To further define the effects of GSK3 on FGF expression, we performed in situ hybridization for FGF18. Consistent with the quantitative PCR results, FGF18 expression was induced following treatment with the GSK3 inhibitor, SB216763 (Figs. 4B and C). Significantly, FGF18 expression is most abundant in the perichondrial cells. This coincides with perichondrial regions wherein h-catenin levels are strongly upregulated adjacent to the hypertrophic chondrocytes in samples without the GSK3 inhibitor (Fig. 4D) . Because inhibition of GSK3 by SB216763 results in stabilization of h-catenin (hcat) and increased levels of hcat protein (data not shown), we hypothesized that hcat is essential for induction of FGF18 expression. To determine if hcat regulates the transcription of FGF18, we performed experiments using the immature osteoblast cell line MC3T3E1. Fig. 5A shows that inhibition of GSK3 induces FGF18 in MC3T3E1 cells. To determine if hcat-dependent transcription is activated in response to inhibition of GSK3, we used TOPFLASH, a luciferase reporter requiring h-catenin/TCF for activation (Korinek et al., 1997) . We found that TOPFLASH activity is stimulated in a dose-dependent manner by SB216763 (Fig. 5B) . To determine if the FGF18 promoter is stimulated by hcat, cells were transfected with a luciferase reporter containing 3.4 kb of the proximal FGF18 promoter. Significantly, the FGF18 promoter was induced when hcat-dependent activity was stimulated by either inhibition of GSK3 with SB216763 or co-transfection of a stabilized form of hcat (Figs. 5C and D) . These data support the conclusion that inhibition of GSK3 induces FGF18 gene expression through upregulation of hcat levels.
We showed that inhibition of GSK3 stimulated FGF expression and repressed chondrocyte differentiation and proliferation. To determine if these findings may be linked, we investigated whether the effects of FGF18 on metatarsal rudiments phenocopy the effects of GSK3 inhibition. Interestingly, we observed similarities between inhibition of GSK3 and activation of FGF signaling with FGF18. Stimulation of metatarsals with FGF18 inhibits both chondrocyte proliferation and differentiation. This is demonstrated by the inhibition of chondrocyte hypertrophy and inhibition of BrdU labeling (Figs. 6A and B) . Also, perichondrial osteoblast differentiation is concomitantly inhibited as evidenced by diminished synthesis of a collar of woven bone (Fig. 6A ), the absence of mature osteoblasts joined by N-cadherin-containing adherens junctions ( Fig.  6C ) and strong repression of type I collagen expression (Fig.  6D) . Also, FGF18 stimulated perichondrial cell proliferation (Fig. 6B, right) , similar to inhibition of GSK3.
These findings suggest that the repression of endochondral bone development resulting from inhibition of GSK3 is in part caused by the induction of FGF expression. To better understand the role of FGF signaling following repression of GSK3, we performed experiments with metatarsals from mice lacking FGF receptor 3 (FGFR3À/À). FGF receptor 3 is expressed in cartilage and is the major receptor for FGF18 in cartilage. Therefore, if the induction of FGF18 contributes to the inhibition of endochondral development, then the inhibition will be diminished in the cartilage of FGFR3 null mice. Consistent with this, we find that in the absence of FGFR3 chondrocyte proliferation was not repressed when GSK3 is inhibited. Fig. 7A shows that as observed previously chondrocyte proliferation is inhibited when GSK3 is inhibited in heterozygous mice. However, inhibition of GSK3 does not repress chondrocyte proliferation in metatarsals from FGFR3À/À mice.
Discussion
Our data have shown that GSK3 activity is essential for endochondral bone development. Inhibition of GSK3 by either lithium or SB216763 strongly inhibits chondrocyte and perichondrial osteoblast differentiation. Because these agents inhibit GSK3 kinase activity by different mechanisms yet similarly repress endochondral bone development, we conclude that the effects of these inhibitors are due to specific inactivation of GSK3 (Coghlan et al., 2000; Ryves and Harwood, 2001 ). The specificity of SB216763 has been validated by evaluation of a large panel of kinases (Coghlan et al., 2000) .
Because GSK3 activity is essential for endochondral bone development, certain substrates of GSK3 are vital regulators of endochondral bone development. There are many putative substrates for GSK3 (Woodgett, 2001) ; however, several well-recognized substrates are central regulators of bone development. The hedgehog signaling pathway activates the transcription factor Gli. Recent data show that the Drosophila ortholog of Gli, cubitus interruptus, is phosphorylated by GSK3 and that this leads to the repression of Gli (Jia et al., 2002; Price and Kalderon, 2002) . Because hedgehog (Indian hedgehog) is expressed in cartilage, we would predict extra Gli activity when GSK3 is inhibited. However, our data suggest less rather than more Gli activity. Patched is a transcription target of Gli (Goodrich et al., 1996) and therefore if Gli activity is stimulated patched expression should increase when GSK3 is inhibited. However, we showed that patched expression is reduced, suggesting reduced rather than increased Gli activity. Our data showing repression of Ihh expression following treatment with the GSK3 inhibitor are consistent with less Gli activity. Therefore, we conclude that Gli does not appear to be the dominant substrate of GSK3 in these experiments. The inhibition Ihh expression may contribute to the regulation of osteoblast differentiation. Osteoblast differentiation is absent in IhhÀ/À mice (Chung et al., 2001; St-Jacques et al., 1999) , suggesting that the reduction of Ihh expression following inhibition of GSK3 contributes to the repression of osteoblast differentiation.
The transcription factors, nuclear factor of activated Tcells are also GSK3 substrates that may regulate chondrocyte differentiation, given that we previously showed that NFAT stimulates chondrogenesis (Tomita et al., 2002) . Because phosphorylation of NFAT by GSK3 inhibits NFAT activity (Beals et al., 1997; Neal and Clipstone, 2001) , we hypothesize that NFAT activity is augmented in metatarsals wherein GSK3 is inhibited. In published work, we show that FGF18 expression is induced through NFAT-dependent pathways (Reinhold et al., 2004a) . Significantly, we now show that FGF18 is induced in response to GSK3 inhibition. This suggests that NFAT may be an important substrate of GSK3 during endochondral bone development. However, NFAT transcriptional activity requires an additional calcium-dependent stimulus that dephosphorylates NFATs via the protein phosphatase calcineurin. We showed that TGFh induces FGF18 activation through a calcium-dependent pathway (Reinhold et al., 2004a) . In addition, data showing that TGFh represses chondrocyte differentiation during endochondral ossification suggest that a TGFh family member may be induced in metatarsal bone rudiments (Bohme et al., 1995; Dieudonne et al., 1994; Serra et al., 1999) . Therefore, we investigated if TGFh expression is induced by GSK3 inhibition. We did not observe changes in the expression of TGFh1, 2 or 3 by QPCR (data not shown). However, our analyses of RNA extracted from the entire metatarsal may not detect a significant induction of TGFh in a discreet population of cells. Further studies will be required to determine if TGFh or another pathway such as the Wnt-calcium pathway can stimulate NFAT activity in developing endochondral bone. Interestingly, NFAT activ- ity can be stimulated by Wnt signaling (Saneyoshi et al., 2002) , therefore, Wnt-calcium signaling is a potential NFAT activator.
hcat is a GSK3 substrate that also has dramatic effects on bone and cartilage differentiation. Phosphorylation of hcat by GSK3 causes degradation by the proteosome. Wnt signaling represses proteolysis of hcat by inhibiting GSK3. Therefore, the inhibition of GSK3 by SB216763 can simulate the effects of Wnt signaling during endochondral development. The effects of Wnt signaling on chondrocytes are complex. Both inhibition and stimulation of differentiation have been observed. Forced expression of Wnt-5a in developing chicken limbs slowed the maturation of chondrocytes as evidenced by diminished expression of type X collagen (Hartmann and Tabin, 2000) . Similar results are obtained when either Wnt5a or Wnt5b is expressed in cartilage of mice . Surprisingly, Wnt5a null mice show the same phenotype of delayed chondrocyte differentiation as mice overexpressing Wnt5a . Moreover, Wnt 4 expression accelerates chondrocyte hypertrophy (Hartmann and Tabin, 2000) . These data show that Wnts can both inhibit and stimulate endochondral bone development. Forced expression of Wnt14 in chondrocytes of mice caused small, dysplastic skeletons, joint fusions and cartilage hypertrophy was strongly repressed (Hartmann and Tabin, 2001 ). Similar observations were seen when a stabilized form of hcat was overexpressed in cartilage implying that the inhibition of endochondral bone development is via canonical Wnt signaling Guo et al., 2004) . Surprisingly, however, cartilage-specific deletion of hcat in chondrocytes also causes formation of a dysplastic skeleton with joint fusions and slowed chondrocyte differentiation Guo et al., 2004; Hu et al., 2005) . While these data indicate that a single simple conclusion cannot account for all effects of Wnt signaling on endochondral bone development, our results support a model wherein the upregulation of hcat levels represses chondrocyte differentiation. Also, while this manuscript was under review, other reports provided evidence for inhibitory effects of Wnt signaling on chondrocyte differentiation Hill et al., 2005) . Significantly, we showed that the expression of FGF18 is induced following inhibition of GSK3. Moreover, we showed that FGF18 is induced through a hcat-dependent pathway. Others have similarly found that FGF18 is induced by hcat . Based on these data and our published data showing that FGF18 is induced through calcium-dependent pathways requiring calcineurin/NFAT activation, we propose that FGF18 is induced via a bipartite pathway when GSK3 is repressed. One pathway simulates canonical Wnt signaling whereby FGF18 is induced after upregulation of hcat protein levels. The second path stimulates FGF18 through calcineurin/ NFAT activation. This model and the effects of FGF18 on cell proliferation in bone rudiments are summarized in Fig. 7B . FGF18À/À mice show features of advanced differentiation including an enlarged hypertrophic region and increased chondrocyte proliferation Ohbayashi et al., 2002) . These results indicate that FGF18 inhibits endochondral differentiation. This is further evidenced by our results showing that FGF18 repressed chondrocyte and osteoblast differentiation and inhibited chondrocyte proliferation. These data mirror the effects on GSK3 inhibition on cultured metatarsals. Given our data showing that FGF18 is induced following GSK3 inhibition, we conclude that GSK3 is an essential regulator of FGF18 expression and that FGF18 is an important downstream mediator of the effects of GSK3 in endochondral bone development. We showed that FGF18 expression is induced by hcat, suggesting that canonical Wnt signaling induced FGF18. Interestingly, the induction of FGF expression through Wnt signaling is essential at several steps of skeletal development. For example, the anatomical site of limb initiation is determined by a Wnt-FGF signaling relay. Wnt2b is expressed in the intermediate mesenchyme of the developing embryo and induces FGF10 expression in the adjacent lateral plate mesenchyme. This relay determines the site for limb development as demonstrated by ectopic limbs that result from forced expression of Wnt2b (Kawakami et al., 2001) . Later during limb development, FGF8 is induced in response to Wnt3 in the ectoderm of nascent limb buds (Barrow et al., 2003; Kawakami et al., 2001 ). This step is critical for both the formation and stability of the apical ectodermal ridge. We propose that the expression of FGF18 in response to hcat is another example of a conserved and essential relay whereby Wnt signaling induces FGF expression during skeletal development. The signaling cascade initiated by the Wnt family of polypeptides controls normal and abnormal development in a variety of tissues (1) (2) (3) . Wnt signaling is initiated by the binding of the extracellular ligand (Wnt) to a seven-transmembrane spanning receptor and coreceptor. The receptor complex is comprised of frizzled, a multiple membrane spanning protein and an low density lipoprotein-related coreceptor, LRP5 or LRP6. The receptor-ligand complex initiates a complex cascade of events. Signals downstream of the Wnt receptor complex are separated into canonical and noncanonical pathways (4) . Canonical Wnt (cWnt) 2 signaling regulates the protein levels of ␤-catenin (␤cat). Within the cytosol ␤cat resides in a multisubunit complex that includes the proteins axin, APC, glycogen-synthase kinase 3 (GSK3) as well as others (5) . In the absence of Wnt, GSK3 phosphorylates specific residues near the amino terminus of ␤cat, leading to its recognition and degradation by a ␤TrCP-dependent proteosome pathway. When Wnt engages its receptor-coreceptor complex, the protein disheveled is recruited to the membrane, phosphorylated, and directed to the APC-AXIN-GSK-␤cat complex where it represses GSK3 activity. Inhibition of GSK3 leads to accumulation of ␤cat and migration to the nucleus. Within the nucleus ␤cat interacts with specific DNA binding transcription factors, most notably the TCF/Lef family of transcription factors (6) . When associated with TCF/Lef, ␤cat recruits other transcription cofactors and stimulates the expression of Wnt target genes. The TCF/Lef transcription factors are a family of 4 proteins that bind to DNA through a conserved high mobility group domain (7) . TCF/Lef proteins transduce cWnt signals into changes in gene expression. In the absence of Wnt, ␤cat levels are low and TCF/Lef proteins act as transcription repressors by recruiting the general transcription inhibitors Groucho/TLE and histone deacetylases (8, 9) . Accumulation of ␤cat in the nucleus leads to direct displacement of Groucho/TLE through the competitive binding of ␤cat to TCF/Lef (10) . ␤cat activates gene expression by recruiting coactivators like p300/CBP (11) and the Mediator complex (12) . cWnt signaling has profound effects on normal cell and tissue development and directly contributes to pathological conditions like neoplasia. During bone formation and remodeling, Wnt signaling is indispensable. Studies of genetically modified mice have contributed much to our understanding of the many functions of Wnt signaling in the skeleton. Gene knockouts of individual Wnts have shown requirements for Wnt10b (13), Wnt5a, , and others during normal skeletal development. To study cWnt signaling during bone growth and remodeling, ␤cat has been conditionally inactivated in several studies. These studies have proven that Wnt signaling is required at several steps during osteoblast differentiation. Inactivation of ␤cat at early steps of osteoblast formation using cre recombinase expressed from the Dermo1, type I collagen, and Prx1 promoters caused aborted osteoblast differentiation (15) (16) (17) . Early osteoblasts expressing the osteoblast transcription factor Runx2 were present, but mature osteoblasts and synthesis of bone matrix was absent. Other studies showed ␤cat requirements at later stages of osteoblastogenesis (18, 19) ; mature osteoblasts failed to develop when ␤cat was deleted at a stage when the transcription factor osterix is expressed, indicating a requirement for cWnt downstream of or coinciding with * This work was supported by National Institutes of Health Grant AR050024 and the Paul Beeson Physician Faculty Scholars in Aging Research Program. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. □ S The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. S1 . 1 osterix. In addition, cessation of cWnt signaling is required for osteoblast maturation (18) . Finally, cWnt signaling also regulates bone osteoclast differentiation and bone resorption by regulating osteoprotegerin expression (20) . Naturally occurring mutations in humans have proven the relevance of Wnt signaling during osteoblast development and for controlling bone mass. A syndromic form of osteoporosis is caused by loss of function mutations in the Wnt coreceptor LPR5 (21) , and a high bone mass phenotype results from mutations in LRP5 that diminish its affinity for Dkk1, an antagonist of Wnt (22, 23) . Thus, in accord with the animal studies, Wnt signals are anabolic for bone and decreased Wnt signaling result in clinically significant bone deficiencies.
Direct Interactions of Runx2 and Canonical Wnt Signaling
These findings have proven the significance of cWnt signaling during osteoblast differentiation. Moreover, these studies suggest that careful stimulation of cWnt signaling or antagonism of ␤cat decay will promote bone formation. Identification of the Wnt target genes that are required for osteoblasts formation in response to cWnt signaling will also signify important pathways that can be modulated for therapeutic benefit of bone disease. In this report we show that the fibroblast growth factor 18 gene (fgf18) is a downstream target of cWnt signaling. FGF18 is expressed in a tissue domain that coincides with (i) sites of osteoblast development and (ii) regions where ␤cat levels (and therefore Wnt signaling) are increased. This implied that fgf18 is a candidate for a Wnt target gene that translates cWnt signaling into osteoblast differentiation. We find that fgf18 is directly induced by cWnt signaling. TCF/Lef proteins bind to a consensus target sequence of the fgf18 promoter and when stimulated by ␤cat induce fgf18 expression. Remarkably, the expression of fgf18 is directly coupled to another essential osteoblast transcription factor, Runx2. Partially overlapping the TCF/Lef site of the FGF18 promoter is a recognition motif for Runx2. Experiments showed that Runx2 interacts with TCF/Lef and forms a ternary complex at the FGF18 promoter. RNA interference experiments showed that Runx2 is necessary for stimulation of FGF18 expression by Wnt, demonstrating that Wnt signaling and Runx2 are both physically and functionally linked. These findings reveal exquisite control of fgf18 expression by two essential osteoblast transcription factors that combine to determine tissue specificity and stimulus dependence. These findings suggest that FGF18 may function as an essential component of the Wnt-dependent steps of osteoblastogenesis that are genetically downstream of Runx2.
MATERIALS AND METHODS
Reagents-SB216763 was from Tocris (Cookson, MO).
Wnt3a conditioned medium was prepared from Wnt3a expressing L-cells according to the suppliers instructions (ATCC, Manassas, VA). Conditioned medium without Wnt3a was made using L-cells.
Plasmids-To create the Ϫ3.3-kb fgf18 reporter plasmid a 3.4-kb MscI fragment of BAC clone RPI 23323L8 was blunt-end cloned into the SmaI restriction site of pGL3basic (Promega, Madison, WI). For the Ϫ1.1-kb reporter plasmid a PvuII/KpnI fragment was excised from the Ϫ3.3-kb plasmid and blunt-end ligated into the SmaI site of pGL3basic. The Ϫ0.8-kb reporter was prepared by SacI digestion of the Ϫ3.3-kb reporter that was cloned into pGL2basic rather than pGL3basic. The released fragment was gel purified and cloned into the SacI site of pGL3basic. MluI digestion of the Ϫ3.3-kb pGL2basic reporter resulted in a DNA fragment that was cloned into the MluI site of pGL3basic. To produce the trimeric repeats, gel purified oligonucleotides or 415-bp fragments having BamHI or BglII sites at opposite ends were kinased, ligated, and fractionated by agarose gel electrophoresis. The trimer was excised from the gel and cloned into the BglII site of pGL3 TATA, a TATA box containing luciferase reporter. pGL3 TATA was created by cloning the oligonucleotide AGATCTGGGTATATAAG-GATCCGGTAAAGCTT and the reverse complement into the BglII/HindIII sites of pGL3basic. Lef1 was cloned into the StuI site of pCS2ϩ following MluI/HindIII digestion and Klenow fill-in of the image clone 6054813. Runx2 (form II) was PCR amplified from a mouse cDNA library using the primers CCGGTACCACCATGCTTCATTCGCCTCA-CAAA and TCTAGATCAATATGGCCGCCAAACAGAC-TCATCCATTCTGCCGCTAGAATTCAA and cloned into pcDNA3.1 (Invitrogen).
Site-directed Mutagenesis-Mutations of the TCF binding site were introduced into the Ϫ1.1-kb and (415) 3 reporter plasmids via QuikChange site-directed mutagenesis following the manufacturer's instructions (Stratagene, La Jolla, CA). The mutations were verified by DNA sequencing. The sequence of the mutagenesis primers is available on request.
Metatarsal Cultures-Metatarsal were dissected from E15.5 day C57Bl/6 embryos and cultured in serum-free medium as described previously (24) . When treated with Wnt3a, the medium was exchanged with conditioned medium (with or without Wnt3a) and the samples were harvested after 24 h.
In Situ Hybridization-4-m sections of paraffin-embedded tissues were processed and hybridized with riboprobes as described previously (25) . The FGF18 riboprobe plasmid was a gift from D. Ornitz (St. Louis, MO).
Immunofluorescence-4-m paraffin sections were prepared as previously described (24) . Primary antibodies were used at a 1:200 dilution (␤-catenin, Santa Cruz sc7963; and FGF18, Santa Cruz sc16830).
Cell Culture and Transfections-MC3T3E1 (clone 14; Ref. 47) and HEK293 were obtained from the ATCC and maintained subconfluent in ␣-minimal essential medium or Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine serum (Hyclone), 2 mM glutamine, penicillin G (100 units/ml), and streptomycin (100 g/ml) at 37°C in a humidified 5% CO 2 incubator. Cells were transfected in triplicate using a modified calcium phosphate precipitation and assayed for luciferase and ␤-galactosidase activity (26, 27) . Luciferase activity was normalized to ␤-galactosidase to control for transfection efficiency.
Real Time Quantitative-PCR-Total RNA was prepared from cells using RNeasy according to the manufacturer's instructions (Qiagen). One g of total RNA was reverse transcribed as described (28) . Real time PCR was done using a SYBR Green PCR mixture (Applied Biosystems) in an ABI 7000 sequence detection system (Applied Biosystems). The sequence of the primers were as reported (28) . Ubiquitin was used as the normalizer.
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RNA Interference-The small interfering RNA oligonucleotide against mouse Runx2 was targeted to GTCCTATGAC-CAGTCTTAC. A negative control shRNA oligonucleotide directed against TTCTCCGAACGTGTCACGT, unrelated to Runx2, was used. The BD Knock-out RNAi System (BD Bioscience) was used for generating small interfering RNAs. Briefly, a double-stranded DNA oligonucleotide containing the shRNA and BamHI and EcoRI overhangs was cloned into the corresponding sites of RNAi-Ready pSIREN-Shuttle vector. The construct was verified by sequencing. MC3T3E1 cells were transiently transfected with shRNA plasmids using Nucleofection (Amaxa Inc., Gaithersburg, MD). 10 6 cells were resuspended in 100 l of Nucleofector solution T and transfected with 5 g of DNA using Program T-20. Transfection efficiency using these conditions was shown to be Ͼ80%. RNA was prepared 24 h post-transfection from cells using an RNeasy (Qiagen) kit according to the manufacturer's instructions.
Chromatin Immunoprecipitation-MC3T3 cells at about 80% confluence were stimulated for 4 h with 20 M SB216763. Thereafter, protein-DNA complexes were cross-linked with 1% formaldehyde for 10 min at room temperature and cross-linking was stopped by the addition of glycine to a final concentration of 0.125 M. Cells were washed with phosphate-buffered saline containing 1 mM phenylmethylsulfonyl fluoride, pelleted at 1200 rpm, and solubilized in swelling buffer (5 mM Pipes, pH 8.0, 85 mM KCl, 0.5% Nonidet P-40, protease inhibitor mixture), incubated on ice for 20 min, and then Dounce homogenized. The nuclei were collected by microcentrifugation and then resuspended in sonication buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, 0.5 mM phenylmethylsulfonyl fluoride, and protease inhibitor mixture) and incubated on ice for 10 min. The samples were sonicated on ice with a Branson Digital Sonifier at 50% amplitude for three 10-s pulses to an average length of ϳ1,000 bp and then microcentrifuged. The sonicated cell supernatant was diluted 4-fold with RIPA buffer (0.1% SDS, 0.1% sodium deoxycholate, 1 mM EDTA, 0.5 mM EGTA, 140 mM NaCl, 10 mM Tris, pH 8) and precleared for 2 h at 4°C with 2 mg/ml salmon sperm DNA, 10 mg/ml bovine serum albumin, and 30 l of Protein G-Sepharose. Prior to use, Protein G-Sepharose was blocked with 0.2 mg/ml of sheared salmon sperm DNA and 1 mg/ml of bovine serum albumin for at least 4 h at 4°C. Precleared chromatin was incubated with antibody and rotated at 4°C for ϳ12-16 h. Antibodies used included anti-␤ catenin (sc-7963, Santa Cruz), anti-Runx C19 (sc-8566, Santa Cruz), and anti-HA (H6908, Sigma). Chromatin-antibody complexes were recovered using 45 l of Protein G-Sepharose slurry. The bound complexes were washed with 1) RIPA lysis buffer (3 times), 2) RIPA lysis buffer plus 0.5 M NaCl (3 times); 3) LiCl buffer (0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris (pH 8) (2 times); and 4) TE buffer (2 times). The samples were then eluted with 1% SDS, 0.1 M NaHCO 3 and cross-links were reversed at 65°C for 4 h to overnight. The samples were than treated for 1 h at 45°C in 200 mM NaCl, 10 mM EDTA, 40 mM Tris, pH 6.8 and 30 g/ml Proteinase K. DNA was recovered by phenol/chloroform extraction and ethanol precipitation. PCR was performed using FGF18 gene primers: 5Ј-CATTCTTTGGGAACCCCGCCT-GCT-3Ј and 5Ј-GGCTGGGTGCGCCGCGCCCACATC-3Ј for 34 cycles (94°C for 45 s; 69°C for 45 s; 72°C for 45 s).
Immunoprecipitation-HEK293 cells were transfected with expression plasmids using a modified calcium phosphate precipitation method (26, 27) . 48 h after transfection the cells were lysed with 1% deoxycholate and 1% Triton X-100, 50 mM Tris, pH 8.0, 0.15 M NaCl, 2 mM EDTA, and 50 g/ml phenylmethylsulfonyl fluoride (Sigma), 0.25 mM orthovanadate (Sigma), and protease inhibitor mixture (Sigma). Clarified lysates were precleared with Protein G-Sepharose (Amersham Biosciences), and then immunoprecipitated with anti-Lef1 (Santa Cruz; sc8591), anti-␤cat (Santa Cruz; sc7199), or anti-hemagglutinin (Sigma; H6908) absorbed to protein G-Sepharose (Amersham Biosciences). Proteins were fractionated by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Milli- pore). Blots were probed with anti-Runx2 (Santa Cruz; sc8566) and detected by chemiluminescence with the West Dura Extended substrate (Pierce).
Nuclear Extracts and EMSAs-Nuclear extracts were prepared as previously described (26, 27) . The protein concentration of extracts was estimated using the BCA protein assay reagent (Pierce). All oligonucleotides encompassing the desired binding site sequences were gel-purified and subsequently annealed. Binding reactions were performed at room temperature for 20 min in a 20-l total volume, which consisted of 0.1 pmol of probe (25,000 cpm), 3 g of bovine serum albumin (Promega), 1.25 g of poly(dI-dC) (Amersham Biosciences), 2-4 g of nuclear protein extract, and buffer D (20 mM HEPES, pH 7.9 (4°C), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM phenylmethanesulfonyl fluoride, 0.5 mM dithiothreitol). Duplex oligonucleotide competitors (specific and nonspecific) were preincubated with the nuclear extract for 5-10 min at room temperature for competition assays. For supershift assays, antibodies were added to nuclear extract and incubated on ice for 20 min, followed by incubation at room temperature for 20 min. The resulting complexes were resolved as described (26) . Anti-Runx2 (sc8566X) was obtained from Santa Cruz.
Animals-The Dermo-1cre deleter strain has been described (29) and mice carrying a floxed allele of ␤cat (30) were obtained from The Jackson Laboratory (Bar Harbor, ME). The animals were maintained in accordance with protocols approved by the Animal Care and Use Committee at University of Texas Health Science Center, San Antonio.
RESULTS
We examined by indirect immunofluorescence the presence of FGF18 and ␤cat in metatarsal bone rudiments isolated from E15.5 mouse embryos. The rudiments were cultured in serumfree medium and differentiated spontaneously. Interestingly, FGF18 protein was found at sites in the perichondrium that coincide with sites of osteoblast differentiation and increased levels of ␤cat (Fig. 1, A and B, and color micrographs in supplementary data Fig. S1 ). We previously determined that FGF18 expression is induced following inhibition of GSK3 (24) . We therefore reasoned that FGF18 is induced by cWnt signaling. In accord with this, fgf18 expression was induced in the perichondrum of metatarsals cultured in medium containing Wnt3a (Fig. 1, C and D) and in cultured cells (Fig. 1E) . To further characterize the regulation of fgf18 by canonical Wnt signaling, we examined fgf18 expression in bones devoid of ␤cat. ␤cat was conditionally inactivated in the developing bones by crossing mice with floxed alleles of ␤cat (30) to the credeleter strain Dermo1-cre (29) . Consistent with the view that canonical Wnt signaling directly induces FGF18 expression, FGF18 transcripts were absent in the perichondrium of bones lacking ␤cat (Fig. 1, F and G) .
To identify the specific targets of Wnt signaling in the fgf18 gene we cloned various portions of the fgf18 promoter into a luciferase reporter vector. Transient transfection of these reporter constructs together with a proteosome-resistant form of ␤cat or following stimulation of the transfected cells with Wnt3a demonstrated that a 415-base pair motif between Ϫ0.8 and Ϫ0.5 kb is stimulated by ␤cat or Wnt3a (Fig. 2, A and B) . This 415-bp sequence was sufficient to respond to ␤cat when cloned into a TATA box containing minimal promoter (Fig.  2C) . Stimulation of this sequence by ␤cat was enhanced when the Wnt-dependent transcription factor, TCF4, was cotransfected (Fig. 2C) . These data indicate that the 415-bp motif is stimulated by cWnt signaling; therefore, we examined this sequence for putative TCF/Lef recognition sites (Fig. 2D) . Three potential binding sites (A, B, and C) were identified. To test the function of these we designed oligonucleotides spanning these sites and determined if 1) the DNA sequence associates with the DNA binding domain of TCF4, and 2) ␤cat-dependent transcriptional activity is apparent in a transient transfection assay. Only site A interacted specifically with the DNA binding domain of TCF4 and showed transcriptional activity when cloned as a trimeric repeat in a luciferase reporter containing a TATA box minimal promoter (Fig. 3, A and B) . Moreover the activation of this sequence by ␤cat was blocked by a form of TCF4 lacking the amino-terminal domain required for interaction with ␤cat (Fig. 3B) . We then mutated the TCF/ Lef site to test its significance. Mutation of the consensus site completely abolished activation by Wnt3a (Fig. 3C ) and ␤cat (data not shown), both of a trimer of the oligonucleotide containing site A, as well as a trimer of the entire 415-bp motif. To determine whether site A can account for activation of the endogenous fgf18 promoter, we introduced the same mutation into the TCF/Lef binding site of the 1.1-kb fgf18 promoter. This mutation also completely abolished the stimulation of the FGF18 promoter by Wnt3a (Fig. 3C) , supporting the view that this site is fully responsible for the activation of the fgf18 gene by Wnt. To determine whether TCF4 and ␤cat interact with the FGF18 promoter in vivo we performed chromatin immunoprecipitation. Following stimulation of MC3T3E1 cells with or without the GSK3 antagonist SB216763 to mimic cWnt signaling, chromatin immunoprecipitation showed ␤cat associated with the FGF18 promoter (Fig. 3D, upper) . Similarly, TCF4 were associated with the FGF18 promoter in HEK293 cells transfected with HA-tagged TCF4 (Fig. 3D, lower) .
We identified a sequence that regulates the expression of fgf18 in response to Wnt. However, Wnts are widely expressed, yet fgf18 expression is much more restricted. This suggested that additional transcription regulators contribute to the expression of fgf18, and that these regulators may functionally cooperate with ␤cat and TCF/Lef to induce fgf18 expression. Significantly, fgf18 expression is greatest in the perichondrium. We then questioned if transactivators expressed in perichondrial cells also regulate fgf18 expression. We searched for clues concerning fgf18 expression by examining the DNA sequence surrounding the TCF/Lef site. Interestingly, a putative Runx2 binding site (TGTGG) partially overlaps the TCF/Lef site (Fig. 2E) . Notably, Runx2 is expressed in the perichondrium, and therefore is a good candidate for a bone cellspecific transactivator that may restrict fgf18 expression to the perichondrium.
To examine effects of Runx2 on fgf18 expression during Wnt activation, we transfected MC3T3E1 osteoblasts with Runx2 and simulated cWnt signaling by inhibiting GSK3 with the pharmacological antagonist SB216763. We chose a concentration of SB216763 that produced submaximal induction of fgf18. Significantly, the combination of Runx2 and SB216763 induced fgf18 to a greater degree (9-fold) than Runx2 in the absence of SB216763 (2.8-fold; Fig. 4A ). Similar results were obtained with Wnt3a (Fig. 4A, right) . Fig. 4B shows that Runx2 did not stimulate the expression of Axin2, a gene that is strongly induced by canonical Wnt signaling (31) . These data therefore suggest a cooperative relationship between Runx2 and TCF/Lef at the FGF18 promoter. This cooperation does not, however, extend to all Wnt-regulated genes, as evidenced by the absence of an effect on Axin2. In fact as shown in Fig. 4B , Runx2 may repress Wnt-dependent induction of Axin2. To further analyze the interaction of Wnt-dependent transcription and Runx2, we diminished Runx2 protein levels by RNA inter- ference knockdown. Knockdown of Runx2 suppressed induction of FGF18 by the GSK3 antagonist and Wnt3a (Fig. 4C) . In contrast, the induction of Axin2 was only modestly effected (Fig. 4D) . These data support a functional interdependence of Runx2 and Wnt-dependent transcription at certain target loci like fgf18. The proximity of the TCF/Lef and Runx2 sites of the fgf18 promoter suggests that these transcription factors may interact directly. To examine this more closely we asked if Runx2 stimulates the FGF18 luciferase reporter plasmids. Fig.  4E shows that Runx2 alone did not stimulate the 3.3-kb FGF18 luciferase reporter (nor fragments thereof; data not show). However, expression of Runx2 together with ␤cat led to dosedependent stimulation of the 3.3-kb fgf18 promoter (Fig. 4F) . At submaximal levels of ␤cat the 3.3-kb FGF18 reporter was stimulated 5.3-fold, whereas ␤cat plus Runx2 stimulated the promoter to 16.6-fold. The 1.1-kb FGF18 reporter was similarly induced by the combination of ␤cat and Runx2 (Fig. 4G) . The costimulation by ␤cat and Runx2 required an intact TCF/Lef site. Mutation of this site abolished stimulation by the combination of Runx2 and ␤cat (Fig. 4H ). The trimer of the A oligonucleotide and the 417-bp motif ( Fig. 5A and data not shown) were also coactivated by ␤cat and Runx2. Fig. 5A shows that whereas Runx2 alone did not stimulate the reporter, Runx2 combined with ␤cat caused a 40-fold activation. This compares with a 9.8-fold stimulation by the indicated amount of ␤cat. Significantly, a TCF/Lef binding site was insufficient for coactivation by Runx2 and ␤cat. In fact, the Topflash reporter, which contains repeats of an optimum TCF/Lef binding site was inhibited rather than activated by the combination of ␤cat and Runx2 (Fig. 5B) . These data predict that Runx2 interacts specifically with the sequence of fgf18. To examine this, we constructed a reporter wherein the potential Runx2 binding site was mutated (A_Runx mut, see Fig. 2E ). Supporting a direct interaction with the Runx2 site, the mutated reporter was not stimulated by Runx2, yet remained inducible by ␤cat, albeit less so (Fig. 5C ). Chromatin immunoprecipitation yields additional evidence that Runx2 interacts with fgf18. Fig. 5D shows that Runx2 is immunoprecipitated with the endogenous fgf18 promoter at the expected site.
These data (Runx2 overexpression, Runx2 shRNA, cotransfection of Runx2 and ␤cat) demonstrate a close functional relationship of Runx2 and the TCF/Lef transcription factors on fgf18. Because the TCF/Lef and Runx2 sites partially overlap, the respective transcription factors may physically interact to regulate the expression of FGF18. To examine this we performed co-immunoprecipitation experiments. First, we examined if ␤cat interacts with Runx2. If ␤cat binds to Runx2, this could explain our finding that ␤cat is required for stimulation of the fgf18 reporters by Runx2. HEK293 cells were transfected with Runx2 or Runx2 and ␤cat. ␤cat was immunoprecipitated and immunoblots for Runx2 were done. The results did not reveal interactions of ␤cat and Runx2 (Fig. 6A) . However, Runx2 binds to both Lef1 and TCF4. Fig. 6 , B and C, shows that Runx2 was co-immunoprecipitated with either Lef1 or HAtagged TCF4. These results demonstrated association of TCF4 or Lef1 with Runx2 in the absence of DNA binding. We next asked whether the proteins also assemble on DNA from the fgf18 gene. EMSA experiments were done using oligonucleotide A and in vitro transcribed and translated Runx2, ␤cat, and Lef1. Fig. 7A shows that Runx2, ␤cat, or combined Runx2 and ␤cat did not form complexes with radiolabeled oligonucleotide A. As expected, Lef1 bound significantly to oligonucleotide A. The combination of ␤cat and Lef1 showed complexes consistent with Lef1 and Lef1-␤cat. Addition of Runx2 to these components led to DNA complexes consistent with Lef1-Runx2 and Lef1-Runx2-␤cat (Fig. 7, A and B) . Addition of an unlabeled oligonucleotide competitor showed these complexes were specific, given that a wild-type DNA sequence was an effective competitor, but an oligonucleotide with a mutation of the TCF/Lef site was not (Fig. 7A ). Therefore these data are consistent with the formation of a complex containing: Runx2-␤cat-Lef1-DNA.
Runx2 did not appear to bind to the DNA sequence of oligo A in the absence of Lef1. Therefore it was not clear if the affinity of Runx2 for DNA was augmented through an association with Lef1 or if Runx2 assembled in a DNA-containing complex solely through protein-protein interactions with Lef1. To determine whether Runx2 binds to oligonucleotide A we did additional competition experiments. For these experiments we prepared nuclear extracts from cells transfected with vector DNA or an expression clone for Runx2. These extracts were incubated with a radiolabeled oligonucleotide containing the Runx2 binding site of the osteocalcin promoter, OSE (32) . Addi- tionally, in the indicated samples we included an anti-Runx2 antibody that produced slower migrating complexes that were more evident on the nondenaturing gels. Fig. 7C shows that oligo A competed for the binding of Runx2 to OSE; both supershifted and nonsupershifted species were disrupted. Competition required an intact Runx2 binding site, as an oligonucleotide containing a mutation in the Runx2 binding site (A_Runx mut ) did not interfere with binding of Runx2 to OSE. Additional control lanes show that unlabeled OSE, but not OSE with a mutated Runx2 site acted as an effective competitor. These data show that Runx2 binds directly to DNA at the FGF18 promoter and support the view that interactions with Lef1 facilitate Runx2 binding to DNA.
DISCUSSION
We showed that the expression of fgf18 is regulated by the combined actions of Wnt-dependent transcription factors TCF/Lef and Runx2. This reflects functional and physical interactions of TCF/Lef and Runx2 at a composite binding site for both transcription factors in the FGF18 promoter. We found that Runx2 and TCF4 or Lef1 form a complex in the absence of DNA and that this complex promotes the binding of Runx2 to its recognition motif in the FGF18 promoter. It is likely that TCF/Lef induces a conformational change in Runx2 that allosterically activates Runx2 DNA binding activity. This is analogous to the interactions of Runx1 and core binding factor ␤ (CBF␤). Binding studies of the runt domain of Runx1 and CBF␤ showed a 5-fold decrease in the Runx1-DNA dissociation constant when Runx1 is bound to CBF␤. NMR studies demonstrated changes in the amide bond backbone of Runx1 upon binding to CBF␤ and the crystal structure show that Runx-CBF␤ has stabilized loop conformations at the site of DNA contact. CBF␤ interacts with the runt domain of Runx1 principally through two surface domains that are opposite the DNA binding interface. This same surface may interact with non-DNA binding domains of TCF4 or Lef1. The DNA bending induced by Lef1 and TCF4 at its recognition site may permit simultaneous protein-protein and DNA-protein interactions, and enhanced affinity of Runx2 for DNA. Whether the high mobility group domain of TCF/Lef and the runt domain of Runx2 are sufficient for this complex is unclear. The amino-terminal glutamine/ alanine-rich region of Runx2 appears to prevent interactions with the Runx1 binding partner, CBF␤ (33) . Perhaps in addition to altering affinity for CBF␤, this domain may selectively contribute to binding with TCF/Lef proteins.
After a Runx2-TCF/Lef complex is bound to DNA how does this complex stimulate the expression of FGF18? Clearly, ␤cat is a key coactivator. The interactions of ␤cat with TCF/Lef are well recognized and in this way histone acetyltransferases like p300 (11) are recruited to the promoter. If ␤cat binds to Runx2, then the activator properties of Runx2 at the FGF18 promoter could be explained by the additional binding energy for ␤cat that is contributed by Runx2. However, ␤cat did not interact with Runx2 by coimmunoprecipitation and gel-shift experiments did not demonstrate disproportionate binding of ␤cat to Lef1-Runx2 complexes. Therefore, we speculate that Runx2 activates the FGF18 promoter through mechanisms distinct from the recruitment of ␤cat. Runx2 may activate expression FIGURE 7 . Assembly of a Lef1-Runx2-␤cat-DNA complex. A, EMSA with radiolabeled oligonucleotide A. The indicated in vitro transcribed and translated proteins were incubated with labeled oligonucleotide and then fractionated on a non-denaturing gel. Where indicated a 100-fold molar excess of unlabeled competitor was added. B, EMSA showing distinct Lef1/Runx2 and Lef1-␤cat-Runx2 complexes. C, EMSA using nuclear extract prepared from cells transfected with Runx2 or a control plasmid and radiolabeled OSE oligonucleotide from the osteocalcin promoter. Where indicated, anti-Runx2 antibody was included to produce supershifted complexes. Where indicated, a 100-fold excess of unlabeled competitor oligonucleotide was added.
through actions such as recruitment of histone acetyltransferases like MOZ and MORF (34) or binding to other transcription factors like AP-1 or Smad (35, 36) . Alternatively, Runx2 may stimulate fgf18 expression through pathways not yet described.
Significantly, a previous report showed that the human FGF18 promoter is stimulated by a ␤cat-TCF complex (37) and that FGF18 contributed to colon cancer cell growth. The sequence of the mouse and human promoters at the TCF/Lef binding site is 100% conserved supporting the significance of this site for FGF18 gene expression. This implies that FGF18 expression is normally targeted to sites where cWnt signaling and Runx2 (and perhaps other members of the Runx family) coincide. We have shown that ␤cat is required for the expression of fgf18 in the perichondrium of long bones during skeletal development. This suggests that both Runx2 and cWnt signaling are required for fgf18 expression under normal physiological states; the absence of either may result in the loss of expression. That is, the physical coupling of TCF/Lef and Runx2 and the juxtaposition of the DNA binding sites specify a cooperative partnership for fgf18 expression. Accordingly, recent data show that Runx2 is essential for fgf18 expression and that Runx2 directly regulates the FGF18 promoter (38) . During pathological conditions like colon cancer, fgf18 may be expressed abnormally and independently of Runx2 as a consequence of excess levels of ␤cat.
The interactions of Runx2 and TCF/Lef do not augment the expression of all Wnt target genes. For example, Axin2 is strongly induced by canonical Wnt signaling, yet its expression is not stimulated by Runx2 (Fig. 4B) . Also, the prototypic Wntdependent reporter plasmid, Topflash, is repressed rather than stimulated by the combination of Runx2 and ␤cat (Fig. 5B) . Kahler and Westendorf (39) also showed that Runx2 binds to Lef1 and this association represses the osteocalcin promoter. Therefore, it is likely that a set of genes are repressed as a consequence of Runx2-TCF/Lef interactions and a different set of genes including fgf18 are induced by the combination. The outcome will be determined by protein-nucleic acid interactions that are promoter-specific. Given the pivotal importance of Runx2 and Wnt-dependent transcription during osteoblast differentiation, the decision to repress or induce gene expression in response to their combined actions will be paramount for temporal and spatial regulation of osteoblast differentiation. For example, recent data show that cessation of Wnt/␤cat activity is required for full maturation of osteoblasts into osteocalcin expressing cells (18) . Coactivation of FGF18 expression by Runx2 and Wnt signaling may support early osteoblast differentiation, but suppress later events. In support of this, we have shown that FGF18 can suppress osteoblast differentiation in cultured metatarsals (24) . Alternatively, strong Wnt signaling may induce TCF1 and/or Lef1 expression that lead to dimerization with Runx2 and dissociation from Runx2-dependent promoters like osteocalcin (39) . In either case, these possibilities imply that a Runx2-TCF/Lef complex will act decisively at specific points during osteoblast differentiation.
We showed that fgf18 is induced via an osteoblast-specific, Wnt-dependent pathway. Thus, fgf18 is a Wnt-target gene that may be essential for translating Wnt signaling into osteoblast development. It is notable that normal osteogenesis is disrupted in fgf18 null embryos (40, 41) . If fgf18 is responsible for the action of Wnt in bone, then based on our understanding of Wnt signaling in bone fgf18 must both stimulate and suppress osteoblast differentiation at different stages of development. How this is achieved will require further investigation; however, expansion of an early osteoblast population through stimulation of cell proliferation will almost certainly be a key attribute of FGF18.
What other genes are induced by the Runx2-TCF/Lef combination? These genes are likely to have both TCF/Lef sites and Runx2 within the promoter; however, given the substantial DNA bending that is induced by the high mobility group domain of Lef (42), we predict that these binding sites need not be directly adjacent or overlapping. The dramatic change in DNA conformation caused by Lef1 can bring a distant Runx2 site into close spatial proximity. We predict that certain of these genes have expression patterns that match closely that of FGF18. Interestingly, Dkk1, tcf1, and Runx2 are induced by Wnt signaling (43) (44) (45) and are expressed in the perichondrium similar to FGF18. Moreover, Dkk1 and tcf1 expression is lost in Runx2 null embryos at sites where Runx2 and Dkk1 or tcf1 are normally coexpressed (46) . Whether these and other genes are coactivated by Runx2 and Wnt-dependent transcription demands further investigation. These genes will surely be vital during osteoblastogenesis and bone formation given that they lay at the convergence of stimulus-dependent and osteoblastspecific transcription pathways that are anabolic for bone.
